ONC
HealthcareBeOne Medicines AG
$320.30
+$9.28 (+2.98%)
Jan 5, 2026
Price History (1Y)
Analysis
BeOne Medicines AG is a biotechnology company listed in the healthcare sector with a market capitalization of $35.44 billion. The company operates on a large scale, employing 11,000 personnel and reporting revenue of $4.97 billion over the trailing twelve months. Financially, BeOne Medicines AG demonstrates strong profitability metrics, including gross, operating, and profit margins of 86.2%, 11.6%, and 1.4% respectively. The company's returns on equity (ROE) and assets (ROA) stand at 1.8% and 1.7% respectively. Its balance sheet shows a substantial cash position of $4.04 billion, while debt accounts for approximately 24.70% of the company's market value. The valuation of BeOne Medicines AG is characterized by an elevated price-to-earnings ratio (TTM) of 593.15 and a forward P/E of 49.69. The company's revenue growth has accelerated to 41.0% year-over-year, indicating a positive trend in its financial performance. However, the dividend yield remains undisclosed due to its N/A status.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Visit website →Key Statistics
- Market Cap
- $35.44B
- P/E Ratio
- 593.15
- 52-Week High
- $385.22
- 52-Week Low
- $172.67
- Avg Volume
- 267.51K
- Beta
- 0.47
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- Switzerland
- Employees
- 11,000